Researchers at the New York Genome Center (NYGC) and Columbia University have uncovered a molecular mechanism behind one of biology's long-standing mysteries: why individuals carrying identical gene mutations for a disease end up having varying severity or symptoms of the disease
All news from Medical Genetics
First-trimester glycated hemoglobin (HbA1c) may aid in early identification of women at risk for gestational diabetes mellitus (GDM), according to a study published online Aug. 16 in Scientific Reports
States that expand eligibility for their Medicaid program in 2014 when the Affordable Care Act (ACA) was implemented, saw fewer uninsured patients among major cardiac-related hospitalizations in the first year compared with states that did not expand the program.
Problems like obesity and alcoholism appear to chronically trigger in the liver a receptor known to amplify inflammation in response to invaders like bacteria, scientists report.
New research finds that blood pressure and cholesterol lowering drugs continue to improve survival in patients with hypertension after more than a decade. Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more than a decade.
The desire for a larger bottom is becoming more popular, with the number of so-called Brazilian butt lifts more than doubling in the last five years. A recent high-profile case in Miami caused the death of a patient during surgery, highlights the risks associated with having this procedure.
When Medicare in 2011 agreed to pay for a revolutionary procedure to replace leaky heart valves by snaking a synthetic replacement up through blood vessels, the goal was to offer relief to the tens of thousands of patients too frail to endure open-heart surgery, the gold standard.
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
Randomized trial results show no benefit of treatment with rivaroxaban (Xarelto, Bayer/Janssen) over placebo in reducing a composite endpoint of symptomatic venous thromboembolism (VTE) or death in patients at increased risk for VTE after discharge from a medical hospitalization.
As a group, breath tests to detect cancer have a relatively high level of sensitivity and specificity, despite the fact that they are still only in experimental stages of development. This is the conclusion from a new meta-analysis of early trials of the concept.